

UNIVERSAL INFLUENZA VACCINES 2022

5-7 September 2022, Richard Doll Building, University of Oxford, Oxford, UK

FINAL ORAL PROGRAMME UIV 2022

SCIENTIFIC ADVISORY PANEL

UIV 2022 Conference Chairman:

Sarah Gilbert (*Pandemic Sciences Institute, University of Oxford, Oxford, UK*)

Ted Ross (*University of Georgia, Athens, Georgia, USA*)

Sean Tucker (*VAXART Inc., South San Francisco, California, USA*)

John Oxford (*Queen Mary University of London, London, UK*)

Christopher Chadwick (*World Health Organization, Geneva, Switzerland*)

Pamuk Bilsel (*FluGen Inc., Madison, Wisconsin, USA*)

Othmar Engelhardt (*MHRA, South Mimms, Potters Bar, UK*)

Tobias Kamphuis (*Janssen Vaccines, Leiden, The Netherlands*)

Anke Huckriede (*University of Groningen, Groningen, The Netherlands*)

Ron Babecoff (*BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel*)

Tamar Ben-Yedidia (*BiondVax Pharmaceuticals Ltd, Ness Ziona, Israel*)

Harry Kleanthous (*Gates Foundation, Seattle, Washington, USA*)

Baozhong Wang (*Georgia State University, Atlanta, Georgia, USA*)

Emanuele Montomoli (*VisMederi Srl, Siena, Italy*)

Otfried Kistner (*VisMederi, Siena, Italy*)

Joanna Waldoock (*MHRA, South Mimms, Potters Bar, UK*)

Vivek Shinde (*Novavax Inc, Rockville, Maryland, USA*)

Yuri Vasiliev (*St. Petersburg Research Institute of Vaccines and Sera, St. Petersburg, Russian Federation*)

Shan Lu (*University of Massachusetts, Worcester, Massachusetts, USA*)

THE
NativeAntigen
COMPANY



VISMEDERI
ANALYSES FOR LIFE IMPROVEMENT

FluConsult
bioscience consultancy & interim management

isirv
International Society for
Influenza and other
Respiratory Virus Diseases

BiondVax
Pharmaceuticals Ltd.

VAXART

DNAvaccine.com

izon
science

福流
nanofcm

08.45 onwards

Registration

09.50-10.00

Welcome & Opening Remarks

Sarah Gilbert

(Pandemic Sciences Institute, University of Oxford, Oxford, UK)

SESSION 1: OPENING PLENARY SESSION

Moderator: Sarah Gilbert

(Pandemic Sciences Institute, University of Oxford, Oxford, UK)

10.00-10.30

'A global perspective on universal influenza vaccines:**What do we want and how will we use it?'**

Christopher Chadwick, Martin Friede and Ann Moen

(World Health Organization, Geneva, Switzerland)

10.30-11.00

'Development of an ELISA-Based Potency Assay for Inactivated Influenza Vaccines Using Cross-Reactive Nanobodies'Chung Y. Cheung¹, Sitara Dubey¹, Martina Hadrovic¹, Christine R. Ball², Walter Ramage², Jacqueline U. McDonald¹, Ruth Harvey¹, Simon E. Hufton² and Othmar G. Engelhardt¹*(¹ Vaccines Division, Scientific Research & Innovation, Medicines and Healthcare products Regulatory Agency, South Mimms, Potters Bar, UK; ² Biotherapeutics Division, Scientific Research & Innovation, Medicines and Healthcare products Regulatory Agency, South Mimms, Potters Bar, UK)*

11.00-11.30

'From a mathematical model of influenza evolution to a novel universal vaccine'

Sunetra Gupta

(Blue Water Vaccines, Cincinnati, Ohio, US)

11.30-12.00

Coffee Break

SESSION 2: UNIVERSAL VACCINES

Moderator: Christopher Chadwick

(WHO, Geneva, Switzerland)

12.00-12.30

'Bill & Melinda Gates Foundation strategy for development of universal influenza vaccines'

Ros Hollingsworth

(BMGF, Seattle, Washington, USA)

12.30-13.00

'The development of a new approach to influenza vaccination, from concept to efficacy testing'

Sarah Gilbert

(Pandemic Sciences Institute, University of Oxford, Oxford, UK)

13.00-14.00

Lunch Break

SESSION 3: GENERAL

Moderator: Anke L.W. Huckriede

(University Medical Center Groningen, Groningen, The Netherlands)

14.00-14.30

'Combining T-cell and Antibody-based approaches to develop more effective influenza vaccines'

Jeffrey Almond

(University of Oxford, Oxford, UK)

14.30-15.00

'Iteratively designed hemagglutinin based H5Nx antigens generate a broad neutralising immune response in mice'

Sneha Vishwanath

(University of Cambridge, Cambridge, UK)

15.00-15.30

Tea Break

SESSION 4: STANDARDISATION/ASSAYS/CORRELATES OF PROTECTION

Moderator: To be confirmed

15.30-16.00

'Standardisation of serology assays used in the evaluation of vaccines'

Othmar G. Engelhardt

(MHRA, South Mimms, Potters Bar, UK)

16.00-16.30

'Correlates of protection for influenza vaccines'

Noemi Guerrini and Emanuele Montimoli

(VisMederi SRI, Siena, Italy)

SESSION 5: GENERAL

Moderator: To be confirmed

09.00-09.30

'The evolution of influenza-specific humoral immune responses and its implications for universal influenza vaccination'

Anke L.W. Huckriede

(University Medical Center Groningen, Groningen, The Netherlands)

09.30-10.00

'Improving the assessment of vaccine efficacy in preclinical trials'

Jose Gonzales Rojas

(Wageningen University, Wageningen, The Netherlands)

10.00-10.30

'Utilisation of the human challenge model for vaccine development'

Brandon Londt and Andrew Catchpole

(hVIVO, London, UK)

10.30-11.00

Coffee Break

SESSION 6: GENERAL

Moderator: To be confirmed

11.00-11.30

'Pandemic influenza vaccine response: The role of new technologies'

Christopher Chadwick

(WHO, Geneva, Switzerland)

11.30-12.00

'Can the principles of a universal flu vaccine design be applied to coronavirus?'

Sunetra Gupta, Brian Price, Erin Henderson and Joe Hernandez

(Blue Water Vaccines, Cincinnati, Ohio, USA)

12.00-12.30

'SEC meets TRPS: Automated isolation and high-precision analysis of extracellular vesicles and viruses'

Camille Roesch¹, Anoop K. Pal², Shayne Harrel³, Robert Vogel² and Murray Broom²

(¹ Izon Science Europe Ltd, Lyon, France; ² Izon Science Ltd, Medford, Massachusetts, USA; ³ Izon Science Ltd, Christchurch, New Zealand)

12.30-13.30

Lunch Break

SESSION 7: VACCINES – I

Moderator: Othmar Engelhardt

(MHRA, South Mimms, Potters Bar, UK)

13.30-14.00

'Evaluation of efficacy, immunogenicity, and cross-reactivity of FLU-v, a universal influenza peptide vaccine tested in a clinical phase IIb trial'

F. Oftung¹, L.M. Næss¹, D. B.-Bratlie¹, I. Laake¹, E. James², G. Stoloff² and O. Pleguezuelos²

(¹ Infection Control and Environmental Health, Norwegian Institute of Public Health, (NIPH) Norway; ² PepTcell Ltd (trading as SEEK), London, UK)

14.00-14.30

'Novel TLR7 adjuvants for universal vaccines'

Akihisa Fukushima

(Sumitomo Pharma Ltd, Japan)

14.30-15.00

Tea Break

SESSION 8: GENERAL

Moderator: To be confirmed

15.00-15.30

'Human T cell immunology of influenza'

Teresa Lambe

(University of Oxford, Oxford, UK)

15.30-16.00

'Title to be confirmed'

Sunetra Gupta

(Blue Water Vaccines, Cincinnati, Ohio, USA)

SESSION 9: VACCINES – II

Moderator: Othmar Engelhardt
(MHRA, South Mimms, Potters Bar, UK)

09.00-09.30

'Results of a Phase 2 study with OXV836 suggest effectiveness in preventing influenza-like illness and confirm good safety profile'

D. Guyon-Gellin², I. Leroux-Roels¹, J. Tourneur², G. Leroux-Roels¹, F. Nicolas², I. P. Willems² and A. Le Vert²
(¹ Ghent University, Ghent, Belgium; ² Osivax, Lyon, France)

09.30-10.00

'Harnessing the clec9a-targeting strategy to boost the immunogenicity of the universal flu antigen vaccine candidate M2e'

Ranmali Kavishna¹, Mireille Lahoud² and Sylvie Alonso¹
(¹ Department of Microbiology & Immunology, Yong Loo Lin School of Medicine; and Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore; ² Department of Biochemistry and Molecular Biology, Monash University, Clayton, Australia)

10.00-10.30

'The pig influenza challenge model'

Barbara Dema Jimenez and Elma Tchilian
(University of Oxford/The Pirbright Institute, Pirbright, Surrey, UK)

10.30-11.00

Coffee Break

SESSION 10: GENERAL

Moderator: Sarah Gilbert
(Pandemic Sciences Institute, University of Oxford, Oxford, UK)

11.00-11.30

'The potential impacts of next generation influenza vaccines in Kenya: A modelling and cost-effectiveness study'

Naomi R. Waterlow¹, Sreejith Radhakrishnan¹, Jeanette Dawa^{2,3}, Edwin van Leeuwen^{1,4}, Philipp Lambach⁵, Joseph Bresee⁶, Marie Mazur⁷, Rosalind M. Eggo¹ and Mark Jit¹

(¹ Centre for Mathematical Modeling of Infectious Disease, London School of Hygiene and Tropical Medicine, London, United Kingdom; ² Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya; ³ Washington State University – Global Health Kenya, Nairobi, Kenya; ⁴ Statistics, Modelling and Economics Department, UK Health Security Agency, London, United Kingdom; ⁵ Immunization Vaccines and Biologicals Department, World Health Organization, Geneva, Switzerland; ⁶ The Task Force for Global Health, Decatur, GA, USA; ⁷ Ready2Respond, USA)

11.30-12.00

'Nano-flow cytometry: A platform for comprehensive virus and extracellular vesicle analysis'

Dimitri Aubert
(NanoFCM, Medicity, Nottingham, UK)

12.00-12.30

Latebreaker talk to be confirmed

12.30-12.40

Closing Remarks and UIV 2022 Conference Close

Sarah Gilbert
(Pandemic Sciences Institute, University of Oxford, Oxford, UK)

12.40

Lunch & Departure

* This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.

CVW 2023 – COVID-19 VACCINES FOR THE WORLD

18-20 April 2023, Richard Doll Building, University of Oxford, Oxford, UK

This new and timely three day international meeting will be devoted to up-to-date developments relating to COVID-19 vaccines currently in use and being developed worldwide to tackle the ongoing COVID-19 pandemic.

COVID-19 VACCINES FOR THE WORLD (CVW 2023) will be aimed at updating the community on the current COVID-19 vaccines in use and those vaccines still under development in the UK, Europe, North America, China and Asia. There will be a focus on the major concerns relating to COVID-19 virus variants and what the requirements will be necessary to enable amended COVID-19 vaccines to counter new virus variants.

There will also be an additional focus, relating to the sister **UIV 2022** meeting, on the potential ongoing problems that may arise with seasonal influenza in 2022 and beyond and the clear evidence that the seasonal influenza in the 2020/2021 was minimal during the COVID-19 pandemic in that period.

If you wish to offer a talk/poster to the **CVW 2023** meeting in Oxford in April 2023 then you can submit this through the participation page on the **CVW 2023** website pages at www.mediconmm.com